Table 1 Sociodemographic and clinical characteristics of 161 participants stratified by current HIV-1 RNA
Total(N = 161) | HIV-1 RNA<400 copies/mL(N = 118) | HIV-1 RNA >400 copies/mL(N = 43) | ||
|---|---|---|---|---|
Gender, N (%) | ||||
Male | 77 (48%) | 60 (51%) | 17 (40%) | |
Female | 84 (52%) | 58 (49%) | 26 (60%) | |
Age (IQR) years | 12.2 (9.3 - 15.3) | 11.6 (8.8 - 14.6) | 13.8 (12.3 - 16.2) | |
Age (categorical) years | ||||
Child (≤12 years old) | 72 (45%) | 63 (53%) | 9 (21%) | |
Adolescent (>12 years old) | 89 (55%) | 55 (47%) | 34 (79%) | |
Time on Treatment (IQR) years | 6.4 (5.3 - 7.5) | 6.3 (5.2 - 7.4) | 6.6 (5.5 - 7.6) | |
1st Line Regimen | AZT or (d4T) +3TC + EFV | 35 (21%) | 28 (24%) | 6 (14%) |
AZT or (d4T) + 3TC + NVP | 60 (37%) | 47 (40%) | 13 (30%) | |
2nd Line Regimen | ABC +3TC + LPV/r | 66 (42%) | 43 (36%) | 24 (56%) |
Adherence as reported by physician, N (%) | ||||
Good | 121 (75%) | 99 (84%) | 22 (51%) | |
Poor | 40 (25%) | 19 (16%) | 21 (49%) | |
WHO Stage | ||||
I | 2 (1%) | 2 (2%) | 0 | |
II | 22 (14%) | 19 (16%) | 3 (7%) | |
III | 92 (57%) | 64 (54%) | 28 (65%) | |
IV | 45 (28%) | 33 (28%) | 12 (28%) | |
+Original HIV-1 RNA, logcopies/mL (IQR) | 1.8 (0 - 5.9) | 1.6 (0 -5.3) | 2.2 (0 - 5.4) | |
CD4 mean absolute number (IQR) | 829 (538 - 1099) | 929 (660 - 1160) | 530 (224 -784) | |
++CD4 absolute number by category | ||||
CD4 < 200, N (%) | 9 (5%) | 3 (3%) | 6 (14%) | |
CD4 201-349, N (%) | 13 (8%) | 4 (3%) | 9 (21%) | |
CD4 350 - 499, N (%) | 13 (8%) | 7 (6%) | 6 (14%) | |
CD4 ≥ 500, N (%) | 112 (70%) | 96 (81%) | 16 (37%) | |
CD4 missing, N (%) | 14 (9%) | 8 (7%) | 6 (14%) | |